Fargue Sonia, Harambat Jérôme, Gagnadoux Marie-France, Tsimaratos Michel, Janssen Françoise, Llanas Brigitte, Berthélémé Jean-Pierre, Boudailliez Bernard, Champion Gérard, Guyot Claude, Macher Marie-Alice, Nivet Hubert, Ranchin Bruno, Salomon Rémi, Taque Sophie, Rolland Marie-Odile, Cochat Pierre
Service de Pédiatrie, Centre de Référence des Maladies Rénales Rares, Hospices Civils de Lyon and Université Lyon 1, Lyon, France.
Kidney Int. 2009 Oct;76(7):767-73. doi: 10.1038/ki.2009.237. Epub 2009 Jul 1.
Primary hyperoxaluria type 1 results from alanine:glyoxylate aminotransferase deficiency. Due to genotype/phenotype heterogeneity in this autosomal recessive disorder, the renal outcome is difficult to predict in these patients and the long-term impact of conservative management in children is unknown. We report here a multicenter retrospective study on the renal outcome in 27 affected children whose biological diagnosis was based on either decreased enzyme activity or identification of mutations in the patient or his siblings. The median age at first symptoms was 2.4 years while that at initiation of conservative treatment was 4.1 years; 6 children were diagnosed upon family screening. The median follow-up was 8.7 years. At diagnosis, 15 patients had an estimated glomerular filtration rate (eGFR) below 90, and 7 children already had stage 2-3 chronic kidney disease. The median baseline eGFR was 74, which rose to 114 with management in the 22 patients who did not require renal replacement therapy. Overall, 20 patients had a stable eGFR, however, 7 exhibited a decline in eGFR of over 20 during the study period. In a Cox regression model, the only variable significantly associated with deterioration of renal function was therapeutic delay with a relative risk of 1.7 per year. Our study strongly suggests that early and aggressive conservative management may preserve renal function of compliant children with this disorder, thereby avoiding dialysis and postponing transplantation.
1型原发性高草酸尿症是由丙氨酸:乙醛酸转氨酶缺乏引起的。由于这种常染色体隐性疾病存在基因型/表型异质性,这些患者的肾脏预后很难预测,而且保守治疗对儿童的长期影响尚不清楚。我们在此报告一项多中心回顾性研究,该研究针对27名受影响儿童的肾脏预后,这些儿童的生物学诊断基于酶活性降低或患者及其兄弟姐妹中突变的鉴定。首次出现症状时的中位年龄为2.4岁,开始保守治疗时的中位年龄为4.1岁;6名儿童是在家族筛查时被诊断出来的。中位随访时间为8.7年。诊断时,15名患者的估计肾小球滤过率(eGFR)低于90,7名儿童已经患有2-3期慢性肾脏病。基线eGFR的中位数为74,在22名不需要肾脏替代治疗的患者中,经过治疗后升至114。总体而言,20名患者的eGFR稳定,然而,7名患者在研究期间eGFR下降超过20。在Cox回归模型中,与肾功能恶化显著相关的唯一变量是治疗延迟,相对风险为每年1.7。我们的研究强烈表明,早期积极的保守治疗可能会保留患有这种疾病的依从性儿童的肾功能,从而避免透析并推迟移植。